Drug Search Results
More Filters [+]

GenSci004

Alternative Names: GenSci004, GENSCI-004, GENSCI 004
Latest Update: 2023-08-31
Latest Update Note: Clinical Trial Update

Product Description

Pegylated Somatropin. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT02976675)

Mechanisms of Action: GHR Replacer

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Changchun GeneScience Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GenSci004

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Hypopituitarism

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ELEVATE

P3

Not yet recruiting

Hypopituitarism

2025-05-01

Recent News Events

Date

Type

Title